Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology, Inc.    ZIOP

ZIOPHARM ONCOLOGY, INC.

(ZIOP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ZIOPHARM Oncology : WaterMill Asset Management Refutes Ziopharm Oncology's Desperate, Low-Road Smear Campaign

11/28/2020 | 05:31pm EST

Highlights That Director Candidate Holger Weis Continues to Receive Public Endorsements From Highly-Respected Biotechnology Leaders, Including Former DemeRx Board Members

Notes That Mr. Weis’ Former Chairman at DemeRx Sees “no Merit to any of the Unsubstantiated Claims Referenced by Ziopharm”

Provides Point-by-Point Rebuttal to Address the False and Unsupported Attacks on Mr. Weis

Urges Shareholders to Look Past Ziopharm’s Distortions and Recognize That Mr. Weis has an Impeccable Track Record – With Zero Employment, Legal or Regulatory Blemishes

WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today responded to the low-road campaign that the incumbent Board of Directors (the “Board”) has apparently initiated in order to smear Holger Weis and misrepresent his more than six-year tenure at DemeRx Incorporated (“DemeRx”). WaterMill believes this seemingly underhanded stunt only reinforces the need for meaningful and urgent boardroom change. It is important to highlight that the incumbent Board’s desperate attack on Mr. Weis comes on the heels of Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy voting advisory firm, recommending that Ziopharm shareholders vote for boardroom change on WaterMill’s WHITE consent card. ISS supports the addition of two WaterMill nominees (Jaime Vieser and Holger Weis) and the removal of two incumbents (Chairman Scott Tarriff and Director Elan Ezickson).

We want to highlight for shareholders that Mr. Weis has unimpeachable integrity and recently received several endorsements from highly-respected biotechnology and life science investors and leaders, including former DemeRx board members. Select endorsements are below.

  1. Henry Mellon, former Chairman of DemeRx, provided the following statement today:

    “I was chairman of the DemeRx board of directors for a significant portion of Holger’s tenure. He demonstrated integrity, professionalism and the highest degree of ethics at every turn – all in the interest of helping DemeRx succeed. Holger is a by-the-book corporate leader that shuns waste and prioritizes efficiency. In my view, there is no merit to any of the unsubstantiated claims referenced by Ziopharm on November 27.”

  2. Skip Clemmons, Managing Director of Stephens Inc. and former DemeRx director, recently stated:

    “I was on the board and Holger, while beginning our relationship as COO/CFO, also took on increasing responsibilities for operations and clinical trials leading to his eventual leadership of the company. In addition, Holger had the novel idea to combine opioids with a small amount of our compound to reduce the abuse liability of opioids, potentially slowing or preventing the onset of tolerance which leads to dependence. A major pharmaceutical company was eager to study this with our company. I found Holger to be fair, thoughtful, and professional in all things related to governance, compensation, and financial reporting. Further, his creative vision for additional applications created new clinical opportunities for us. Holger is a great leader, a generous colleague, a good man, and a solid contributor at the board level as well as management. I am proud to call him a friend and would be happy to work with him again.”

  3. James Barlow, President & Chief Executive Officer of ImmunoGenesis, Inc., recently stated:

    “I have a high regard for Holger’s deep expertise for operating Biotech companies. From his distinguished career as a C-suite Executive at numerous Biotechs, Holger [...] would be a real asset in sharpening the operational focus at Ziopharm. He is refreshingly candid and has unquestioned integrity, which will allow him to be a strong, credible voice for change at the Company.”

  4. Hector J. Gomez MD PhD, Executive Chairman & Chief Medical Officer of GLG Pharma, LLC, recently stated:

    “[Holger has] a myriad of proficiencies that are invaluable for a pharma or biotech organization. I was amazed at the proficiency that he has with regulatory issues, clinical trial design, fundraising and just a general ‘solve-all-problems’ attitude. His relentless pursuit of success is admirable.”

In keeping with its apparent disregard for honest investor communication, the incumbent Board’s misleading press release on November 27th is full of cherry-picked quotes and completely unsubstantiated claims from a filing made by DemeRx during its 2018 bankruptcy. The incumbent Board’s press release does not acknowledge that Mr. Weis spent more than six years as an executive in good standing, enjoys the support of former DemeRx directors and was owed hundreds of thousands of dollars at the time of the organization’s bankruptcy. The press release also fails to acknowledge that DemeRx, which was under new leadership in 2018, was choosing to fight Mr. Weis rather than honor his claims as a creditor. The reality is that DemeRx’s founder and current chief executive officer, who was previously terminated by the board of directors in 2013, did not want to honor Mr. Weis’ claims once she was back in control.

We believe it is important to set the record straight now that Ziopharm is apparently trying to smear Mr. Weis:

  • Distortion #1: Ziopharm states that “a majority of shareholders executed written consents to remove Mr. Weis” from his positions at DemeRx.
    • The Reality: This statement is false. Mr. Weis was not a director of DemeRx and, therefore, could not be removed by written consent. Mr. Weis had a provision in his employment agreement that allowed him to resign for “good reason” if DemeRx’s founder and current chief executive officer ever returned. This is why Mr. Weis resigned on July 24, 2017.
  • Distortion #2: Ziopharm is apparently trying to mislead shareholders by repeating DemeRx’s unsupported claim that Mr. Weis made “inaccurate and misleading presentations” to his board of directors that resulted in “excessive remuneration.”
    • The Reality: Ziopharm is recycling false and unsubstantiated claims. Mr. Weis was evaluated by DemeRx’s board of directors for years, including its compensation committee and audit committee. He never made inaccurate and misleading statements to the board of directors. In addition, he was not in a position to influence what the board of directors deemed to be his appropriate compensation.
  • Distortion #3: Ziopharm is apparently trying to mislead shareholders again by citing DemeRx’s baseless contentions that Mr. Weis received “excessive compensation based on milestones never achieved” and “made unauthorized payments to himself.”
    • The Reality: Ziopharm is recycling more false and unsubstantiated claims. Mr. Weis submitted performance self-appraisals to the board of directors for its independent assessment throughout his more than six-year tenure. Any and all compensation received by Mr. Weis during his tenure at DemeRx was approved and authorized by the board of directors (which Mr. Weis was not a part of). Notably, Mr. Weis voluntarily worked without a salary and bonus throughout 2017 in order to help DemeRx allocate capital to other key business initiatives. He always acted in DemeRx’s best interest.
  • Distortion #4: Ziopharm apparently wants shareholders to believe Mr. Weis was responsible for millions of dollars of “waste” at DemeRx.
    • The Reality: Ziopharm is continuing to cite more false claims. Soon after joining DemeRx, Mr. Weis helped improve cost controls and he ultimately delivered tangible clinical progress on a very efficient budget. In fact, Mr. Weis was lauded for his cost efficiency by the board of directors (including members who continue to publicly support him today).
  • Distortion #5: Ziopharm wants shareholders to believe Mr. Weis was responsible for wasting funds on excessive patent-related legal fees at DemeRx.
    • The Reality: The claim being echoed by Ziopharm is baseless. Given that DemeRx had limited intellectual property at the onset of its development program, creating new patents was an important and essential strategic initiative towards building the business. The legal advisory work commissioned by Mr. Weis was regularly reviewed by the board of directors.

Robert Postma, principal and founder of WaterMill, concluded:

“Ziopharm’s incumbent Board never fails to disappoint when it comes to taking the low road. This attempt to smear Holger with baseless and unsubstantiated claims is just the latest instance of the incumbents’ desperation. It is clear to us that Scott Tarriff and his allies in the boardroom simply want to divert attention away from Ziopharm’s abysmal corporate governance, dismal business decisions, wasteful spending and value-destructive tailspin. Unfortunately for them, WaterMill will continue to make this contest about the issues that matter to shareholders. Holger, Jaime and I are committed to joining the Board and helping Ziopharm veer off its current path to financial ruin. WaterMill is also committed to Holger and encourages shareholders to focus on the facts pertaining to his robust credentials, quality endorsements and proven integrity.”

***

We urge Ziopharm shareholders to consent to all five proposals on the WHITE consent card today by signing, dating and returning it in the postage-paid envelope provided. Please vote each and every WHITE consent card you receive since you may own multiple accounts. If you have already voted a Green revocation card from Ziopharm, a later-dated vote on the WHITE consent card will revoke that vote.

December 11, 2020 is our goal for the submission of written consents. Effectively, this means that you have until December 11, 2020 to consent to the proposals.

You may only consent by voting the WHITE consent card. Please throw away all Green revocation cards you receive.

***


© Business Wire 2020
All news about ZIOPHARM ONCOLOGY, INC.
01/14ZIOPHARM ONCOLOGY INC : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
01/14ZIOPHARM ONCOLOGY : Announces Election of James Huang as Chairman of the Board o..
AQ
01/06INSIDER TRENDS : 90-Day Insider Selling Trend Continued at ZIOPHARM Oncology
MT
2020ZIOPHARM ONCOLOGY INC : Notice of Delisting or Failure to Satisfy a Continued Li..
AQ
2020Ziopharm to Participate in Upcoming January Conferences
GL
2020ZIOPHARM ONCOLOGY : Announces Clearance of Taiwan's First IND of Non-viral CAR-T..
AQ
2020ZIOPHARM ONCOLOGY : Joint Venture Gets Taiwanese Regulatory Nod for Phase 1 Stud..
MT
2020Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-..
GL
2020ZIOPHARM ONCOLOGY INC : Notice of Delisting or Failure to Satisfy a Continued Li..
AQ
2020ZIOPHARM ONCOLOGY : Shares Rise 2% After Investor WaterMill Secures Support for ..
MT
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -78,2 M - -
Net cash 2020 116 M - -
P/E ratio 2020 -11,4x
Yield 2020 -
Capitalization 902 M 902 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 73
Free-Float 93,5%
Chart ZIOPHARM ONCOLOGY, INC.
Duration : Period :
ZIOPHARM Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIOPHARM ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 5,93 $
Last Close Price 4,24 $
Spread / Highest target 77,1%
Spread / Average Target 40,0%
Spread / Lowest Target -29,2%
EPS Revisions
Managers and Directors
NameTitle
Laurence James Neil Cooper Chief Executive Officer & Director
Zuie Chin Huang Chairman
Lynn M. Ferrucci SVP-IT, Human Resources & Administration
Raffaele Baffa Chief Medical Officer
Heidi M. Hagen Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY, INC.68.06%902
GILEAD SCIENCES, INC.12.39%82 081
WUXI APPTEC CO., LTD.36.65%63 102
VERTEX PHARMACEUTICALS-4.69%58 574
REGENERON PHARMACEUTICALS6.72%54 415
BEIGENE, LTD.24.12%29 244